证券代码：301130 证券简称：西点药业 公告编号：2025-061 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金及自有资金进行现金管理和委托理财 到期赎回并继续进行现金管理和委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-060 吉林省西点药业科技发展股份有限公司 关于召开 2025 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届董事 会第十二次会议审议通过，决定于 2025 年 9 月 2 日（星期二）14:30 召开 2025 年 第 一 次 临 时 股 东 会 。 公 司 已 于 2025 年 8 月 15 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露了《关于召开 2025 年第一次临时股东会的通知》， 本次股东会采用现场投票和网络投票相结合的方式召开，现将本次股东会的有关 事宜再次提示如下： 一、 召开会议的基本情况 1、会议届次：2025 年第一次临时股东会 2、会议召集人：董事会。 3、会议召开的合法、合规性：第八届董事会第十二次会议审议通过了关于 召开本次股东会的议案。本次股东会会议的召开符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的有关规定。 4、会议召开的日期 ...

关于公司枸橼酸钙获得化学原料药上市申请批准通知书的公告 证券代码：301130 证券简称：西点药业 公告编号：2025-058 吉林省西点药业科技发展股份有限公司 通知书编号：2025YS00737 登记号：Y20240000005 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）签发的枸橼酸钙《化学原料药上 市申请批准通知书》。现将相关情况公告如下： 一、药品的基本情况 药品名称：枸橼酸钙 剂型：原料药 包装规格：15kg/桶 注册标准编号：YBY68642025 生产企业名称：吉林省西点药业科技发展股份有限公司 生产企业地址：吉林市龙潭区汉江路 2 号 二、药品相关情况简介 枸橼酸钙为钙剂，适用于预防和治疗多种钙缺乏症。临床上用于预防和治疗 骨质疏松、手足抽搐症、骨发育不全、佝偻病；儿童、妊娠和哺乳期妇女、绝经 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-059 近日，公司使用闲置募集资金和自有资金进行现金管理和委托理财到期赎回 并继续进行现金管理和委托理财，现就具体情况公告如下： 签约机构 产品名称 产品类型 金额 （万元） 产品起 息日 产品到 期日 年化 收益率 赎回本金 （万元） 本次收 益（万 元） 资金 来源 平安银行股 份有限公司 长春分行 平安银行对 公结构性存 款 保本浮动 收益型结 构性存款 1,200.00 2025/05 /21 2025/08 /20 1.81% 1,200.00 5.42 募 集 资金 广发证券股 份有限公司 广发骐骥悠 享 2 号集合 资金信托计 非保本浮 动收益型 3,000.00 2025/02 /14 2025/08 /18 3.31% 3,000.00 50.37 自 有 资金 一、使用闲置募集资金和自有资金进行现金管理和委托理财赎回的情况 | | | 划 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

天眼查商业履历信息显示，吉林省西点药业科技发展股份有限公司，成立于1990年，位于吉林市，是一 家以从事医药制造业为主的企业。企业注册资本7649.4685万人民币，实缴资本3080.9903万人民币。公 司法定代表人为张俊。 通过天眼查大数据分析，吉林省西点药业科技发展股份有限公司共对外投资了3家企业，参与招投标项 目345次，知识产权方面有商标信息42条，专利信息16条，此外企业还拥有行政许可83个。 来源：金融界 金融界消息 截至2025年8月25日收盘，西点药业（301130）报收于32.75元，上涨0.52%，换手率 5.25%，成交量3.07万手，成交金额1.01亿元。 资金流向方面，今日主力资金净流出1524.54万元，占比成交额15.14%。其中，超大单净流出1206.32万 元、占成交额11.98%，大单净流出318.22万元、占成交额3.16%，中单净流出流入862.63万元、占成交 额8.57%，小单净流入661.92万元、占成交额6.58%。 西点药业最新一期业绩显示，截至2025中报，公司营业总收入1.28亿元、同比减少0.51%，归属净利润 2494.46万元，同比增长2.02%， ...

Group 1 - The stock price of West Point Pharmaceuticals is reported at 34.01 yuan, reflecting a decline of 1.25% compared to the previous trading day [1] - The company operates in the chemical pharmaceutical sector, focusing on the research, development, production, and sales of pharmaceutical products [1] - On August 18, the net outflow of main funds for West Point Pharmaceuticals was 7.9453 million yuan, with a total net outflow of 19.4002 million yuan over the past five days [1] Group 2 - The trading volume on the same day was 34,174 hands, with a total transaction amount reaching 116 million yuan [1]

Core Viewpoint - The stock price of West Point Pharmaceuticals is reported at 34.44 yuan, reflecting a 1.00% increase from the previous trading day, indicating positive market sentiment towards the company [1] Company Summary - West Point Pharmaceuticals operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceuticals [1] - For the first half of 2025, the company reported a revenue of 128 million yuan and a net profit attributable to shareholders of 24.94 million yuan, along with a net cash inflow from operating activities of 33.71 million yuan [1] Market Activity - On August 15, the company experienced a net outflow of 13.72 million yuan in principal funds, with a cumulative net outflow of 1.36 million yuan over the past five days, suggesting some selling pressure in the market [1]

Group 1 - The company has not declared any cash dividends or bonus shares during the reporting period [3] - The company received several approvals from the National Medical Products Administration for its products, including sodium hyaluronate eye drops and antiviral tablets [5] - The company held its eighth board meeting on August 14, 2025, where various reports and proposals were approved [40][41] Group 2 - The company reported a total fundraising amount of RMB 455.53 million from its initial public offering, with a net amount of RMB 390.93 million after expenses [27][28] - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests [30] - As of June 30, 2025, the company has used RMB 44.55 million of its excess fundraising to permanently supplement its working capital [33][35] Group 3 - The company plans to hold its first extraordinary general meeting of 2025 on September 2, 2025, to discuss various proposals [8][52] - The meeting will allow shareholders to vote both in person and online, ensuring accessibility for all stakeholders [9][10] - The company has made amendments to its internal management systems to enhance operational efficiency and compliance with legal requirements [7][50]

（文章来源：证券日报） 证券日报网讯 8月14日晚间，西点药业发布公告称，公司将于2025年9月2日召开2025年第一次临时股东 会。本次股东会将审议《关于修订公司部分制度的议案》等。 ...

Core Insights - West Point Pharmaceutical (301130) reported a revenue of 128 million yuan for the first half of 2025, a year-on-year decrease of 0.51%, while net profit attributable to shareholders increased by 2.02% to 24.94 million yuan [1] - The company focuses on the research, production, and sales of chemical raw materials and formulations, with a strong emphasis on precision treatment for chronic diseases prevalent among the elderly, iron supplementation, and psychiatric medications [1] Group 1 - The decrease in revenue is attributed to the company's active market expansion and growth in sales of key products such as Rhizoma Alismatis capsules and Risperidone orally disintegrating tablets [1] - The company holds 29 registered formulations (36 specifications) and 16 registered raw materials, focusing on chronic disease treatments, anemia, circulatory disorders, and psychiatric medications [1] Group 2 - Rhizoma Alismatis capsules are a core product with clear pharmacological activity and clinical application value, supported by multiple invention patents in synthesis and application [2] - The company is the only domestic producer of Rhizoma Alismatis raw materials and capsules, actively researching new indications for the product, including complications from diabetes [2] Group 3 - In the field of psychiatric medications, the main products include Risperidone orally disintegrating tablets and Escitalopram oxalate tablets, with the company being the first to market the former [3] - The company is expanding its market share by leveraging its vertical integration model of "raw materials + formulations," ensuring high standards and consistency in product quality [3]